Walmart's warehouse arm, Sam's Club, rolls out pilot healthcare program to members

October 08, 2019
Digital Transformation More...
Very important

Walmart's partnerships with telehealth provider 98point6 and diagnostics giant Quest not only reduce healthcare prices but also stabilize the company's outlook. Walmart's business model has historically been based on selling cheap goods from China at low prices and then leveraging its buying power over other manufacturers to reduce prices from local producers. With a trade war underway and increasing talk of an economic downturn, by meeting consumer demand for affordable (and largely preventative – read: lower-cost) healthcare, Walmart is bracing itself against economic uncertainty. Clients should be looking to branch into healthcare not only for financial ROI, but also as protection against similar uncertainties.

For the original news article, click here .

Further Reading

Center for Medicaid and Medicare Services proposes making U.S. telehealth expansion rules permanent but will not reimburse providers

News Commentary | June 30, 2020

There are two potential consequences from the decision not to reimburse: 1) telehealth use by providers will drop precipitously, and 2) costs will be put on the consumer directly, which will either cause current advancements to fizzle or drive the creation of a more price‑sensitive market (Walmart ... To read more, click here.

Genius 2020: Leveraging Crisis

State of the Market Report | September 25, 2020

A crisis of epic proportions is upon us. Many of the fundamental assumptions we have held true about human health, free markets, the nature of work, consumption, and movement of people and goods ‑ to name but a few ‑ are being stressed to points previously unthinkable. Given the magnitude of change ... Not part of subscription

Walmart's low-cost insulin promises to revolutionize insulin access and affordability for diabetic patients in U.S.

News Commentary | July 02, 2021

Insulin prices are more than eight times higher in the U.S. than in 32 high‑income nations. Insulin's out‑of‑pocket (OOP) costs also continue to rise in the U.S., although net costs to pharmacy benefit managers (PBMs) are dropping. These facts underscore the grim reality for more than 10 million ... To read more, click here.